News & Events about Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX Get Rating) has earned an average rating of Moderate Buy from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have given a buy ...
Business Wire
2 months ago
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, November...
Ticker Report
2 months ago
Amylyx Pharmaceuticals (NASDAQ:AMLX Get Rating) had its target price upped by Citigroup to $51.00 in a research note published on Wednesday morning, Stock Target Advisor reports. Several other brokerages have also commented on AMLX. The Goldman Sachs Group increased their price target on ...
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video PR Newswire CAMBRIDGE, Mass., Oct. 18, 2022 View the Nasdaq Opening Bell Ringing & CEO Message...